Sanofi/Genzyme expect US Lemtrada decision in 2nd half, while Aubagio's footprint growing
This article was originally published in Scrip
If things go smoothly from this point on, Genzyme and its parent company Sanofi could have a decision from the US FDA in the second half of this year on the firms’ supplemental biologics license application (sBLA) to market Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis (RMS), with the medicine granted a standard review.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.